SCHEDULE 13G/A: Key Insider and Entity Disclose Significant Stakes in Atea Pharmaceuticals

JPM Partners LLC and Jean-Pierre Sommadossi have disclosed significant beneficial ownership stakes in Atea Pharmaceuticals, Inc., with Dr. Sommadossi holding 10.1% of the common stock.

Summary

• JPM Partners LLC beneficially owns 5,866,025 shares of Atea Pharmaceuticals, Inc. common stock, representing 6.9% of the class.
• Jean-Pierre Sommadossi beneficially owns a total of 8,876,453 shares of Atea Pharmaceuticals, Inc. common stock, representing 10.1% of the class.
• Dr. Sommadossi's total beneficial ownership includes 3,010,428 shares held directly and shared beneficial ownership of the 5,866,025 shares held by JPM Partners LLC, where he serves as manager.
• His direct holdings include 2,709,488 shares of common stock subject to stock options that are currently exercisable or will become exercisable within 60 days of March 31, 2025.
• The beneficial ownership percentages are calculated based on 85,579,475 shares of common stock outstanding as of May 9, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on May 12, 2025.

Sentiment

Score: 6

Explanation: The filing is a standard disclosure of beneficial ownership, indicating a significant stake held by an insider and an associated entity. This is generally a neutral event, but the substantial insider ownership could be viewed as a positive signal of confidence.

Positives

• The disclosure of a significant beneficial ownership stake by an insider (Jean-Pierre Sommadossi) and an associated entity (JPM Partners LLC) may signal confidence in the company's future prospects.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard regulatory disclosure of significant ownership and does not provide specific insights into broader industry trends or competitive dynamics beyond the ownership structure of Atea Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant beneficial ownership stakes held by JPM Partners LLC and Jean-Pierre Sommadossi, which can influence investor perception and potentially share price.

Key Dates

Keywords

Atea Pharmaceuticals, ATPA, Schedule 13G, beneficial ownership, common stock, Jean-Pierre Sommadossi, JPM Partners LLC, SEC filing, ownership stake